A Phase 2 interventional study of IRX-101 and Providone-Iodine in Retinal Disease, sponsored by iRenix Medical, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by iRenix Medical, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.
Among the 162 studies in Retinal Diseases with a site in United States, this one is the 26th largest by enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2023, is one of 25 in phase 2, and was the 138th registered.
333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.
Browse Retinal Diseases studies →25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
Duke University · Sites in United States
Ages 1 mo+ · Healthy volunteers
Life Biosciences Inc. · Sites in United States
Ages 40–85
Washington University School of Medicine · Sites in United States
Ages 50+
MediBeacon · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 49 · Phase 3 21 · Phase 4 1
First in 1992; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 51 across 207 interventional studies indexed under Retinal Diseases.
Median enrollment 36 across the 111 interventional studies, 120 across the 51 observational. Of the 113 that completed or were terminated, 44 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 162 have an industry lead sponsor. The 10 most frequent:
iRenix Medical, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
iRenix Medical, Inc. has 2 studies filed under Retinal Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Retinal Diseases with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT05750589Phase 3iRenix Medical, Inc.Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections | 2027-01-31 |
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT06380075University of Wisconsin, MadisonCOmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 162 studies in Retinal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 15 centers in the United States (US).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to IRX-101 will receive the investigational product, IRX-101.
Drug: IRX-101
Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.
Drug: Providone-Iodine
IRX-101 is a novel ocular anti-septic
5% Providone-Iodine
Safety of new drug
Safety will be measured via slit lamp and fundoscopic examinations
Time frame: 1-hour and 1-week post-treatment
Mean corneal fluorescein staining scores
Compare mean corneal fluorescein staining scores obtained after IVT in the IRX-101 and standard of care groups; corneal staining will be obtained using the validated Oxford Corneal Staining scale of 0 (no staining) to 5 (maximal staining)
Time frame: Immediately following intraviteral injection
Patient-reported post-injection pain scores
Compare mean patient-reported post-injection pain scores 1-hour post-administration; pain will be assessed using the visual analog pain scale, a validated patient-reported outcome measure (questionnaire) for assessing patient's subjective pain and discomfort
Time frame: 1-hour post-administration
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Mar 2025, 24 months.
Of 18 phase 2 interventional studies under Retinal Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 38. This study's 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IRX-101